Does Dr. FERNANDO YSERN BORRAS have financial conflicts of interest?

Dr. FERNANDO YSERN BORRAS (M.D.) has received a total of $51,703 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $47,895 in personal promotional payouts (consulting, meals, travel) and $3,807 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. FERNANDO YSERN BORRAS?

According to CMS Open Payments data, Dr. FERNANDO YSERN BORRAS received funding from VALNEVA USA ($26,505), TAKEDA PHARMACEUTICALS U.S.A ($14,582), and MERCK SHARP & DOHME ($5,050).

Does Dr. FERNANDO YSERN BORRAS receive research grants or speaking fees?

Dr. FERNANDO YSERN BORRAS has received $47,895 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $3,807 in clinical research grants.

DR. FERNANDO YSERN BORRAS

M.D.Real-Time Hydrated

Specialty: Pediatrics

Practice Location: CAGUAS, PR 00725

NPI Number: 1376549790

LIFETIME INDUSTRY VALUE

$51,703

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. YSERN BORRAS is a verified Pediatrics practitioner based in CAGUAS, PR.

Between 2021 and 2025, Dr. YSERN BORRAS had an overall industry promotional and research financial footprint of $51,703 as recorded in the federal CMS Open Payments database.

$47,895 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$3,807 was allocated to sponsored clinical trials and medical research activities.

Dr. YSERN BORRAS's primary funding source is VALNEVA USA, which accounts for $26,505 (representing 51.3% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

VALNEVA USA

Rank 1

$26,505

51.3%

TAKEDA PHARMACEUTICALS U.S.A

Rank 2

$14,582

28.2%

MERCK SHARP & DOHME

Rank 3

$5,050

9.8%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.